TRIP4 and breast cancer: As to the findings that estrogen-induced ASC1 ufmylation is required for ERα transactivation and tumor formation (22), UBA5 and other components of UFM1-conjugating machinery involved in ASC1 ufmylation could be used as potential targets for development of new therapeutic drugs against ERα-positive breast cancer.